Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
1998-3-19
|
pubmed:abstractText |
Previous researchers have identified two sequences present upstream (angiotensinogen gene-activating element [AGE2]) and downstream (d61-2) of the human angiotensinogen gene that act as cell-specific enhancers of transcription in transiently transfected HepG2 cells. To examine the importance of these two sequences in regulating tissue- and cell-specific expression of the gene in vivo, we generated transgenic mice containing the mutations in the context of a genomic transgene previously shown to exhibit appropriate tissue and cell specificity. The ability of these sequences to enhance transcription of a basal human angiotensinogen promoter was confirmed in transient transfection assays in HepG2 cells, and mutations within the AGE2 and d61-2 sequences abolished transactivation of the promoter. Tissue- and cell-specific expression was examined in three lines of transgenic mice carrying the d61-2 mutation, two lines of transgenic mice carrying the AGE2 mutation, and three founder transgenic mice carrying a double-mutant construct. Although the absolute levels of expression varied among lines, the pattern of tissue-specific expression was essentially unaltered by the mutations. In situ hybridization confirmed that the mutations were also dispensable for proximal tubule-specific expression within the kidney. Finally, a comparison of transgene expression with transgene copy number revealed a direct proportionality in liver (R=.77, P=.0014) and kidney (R=.76, P=.0024). These results clearly demonstrate that these sites, which strongly induce promoter activity in cells in culture, are not required for appropriate expression of the gene when present in a genomic construct in vivo.
|
pubmed:grant | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Mar
|
pubmed:issn |
0194-911X
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
31
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
734-40
|
pubmed:dateRevised |
2008-11-21
|
pubmed:meshHeading |
pubmed-meshheading:9495255-Angiotensinogen,
pubmed-meshheading:9495255-Animals,
pubmed-meshheading:9495255-Enhancer Elements, Genetic,
pubmed-meshheading:9495255-Gene Expression,
pubmed-meshheading:9495255-Gene Transfer Techniques,
pubmed-meshheading:9495255-Genes, Reporter,
pubmed-meshheading:9495255-Humans,
pubmed-meshheading:9495255-In Situ Hybridization,
pubmed-meshheading:9495255-Kidney,
pubmed-meshheading:9495255-Mice,
pubmed-meshheading:9495255-Mice, Inbred C57BL,
pubmed-meshheading:9495255-Mice, Transgenic,
pubmed-meshheading:9495255-Mutagenesis,
pubmed-meshheading:9495255-Mutation,
pubmed-meshheading:9495255-Regulatory Sequences, Nucleic Acid,
pubmed-meshheading:9495255-Tumor Cells, Cultured
|
pubmed:year |
1998
|
pubmed:articleTitle |
Regulatory elements required for human angiotensinogen expression in HepG2 cells are dispensable in transgenic mice.
|
pubmed:affiliation |
Department of Anatomy, The University of Iowa College of Medicine, Iowa City 52242, USA.
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|